Skip to content

The influence of dropsize of tropicamide eyedrops on pupildilation

The influence of dropsize of tropicamide 0.5% eyedrops on pupildilation - MICRO1

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2012-005219-18-NL
Enrollment
Unknown
Registered
2012-12-19
Start date
2013-01-17
Completion date
Unknown
Last updated
2013-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pupil diagnostics

Interventions

Trade Name: Tropicamide Pharmaceutical Form: Eye drops, solution in single-dose container INN or Proposed INN: tropicamide Other descriptive name: TROPICAMIDE Concentration unit: % percent Concentrati

Sponsors

St. Elisabeth Ziekenhuis
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: age between18-64 years informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 28 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: eye disease, risk factors for angle-closure glaucoma, previous eyetrauma/surgery, dioptric value >+6, cardiac disease, diabetes, medication for the eye, medication influencing pupildiameter, substance abuse, (possible) pregnancy, breastfeeding

Design outcomes

Primary

MeasureTime frame
Main Objective: Is the degree of pupildilation, achieved after administrating a 4.5 microliter microdrop tropicamide 0.5% equivalent to the pupildilation after a regular 30 microliter eydrop tropicamide 0.5% in healthy volunteers? ;Secondary Objective: Is there a subjective difference in the degree of physical discomfort, experienced after administration of a microdrop compared to a regular eyedrop? Qualitative evaluation of the mydriatic reponse/time curves of both the microdrop and the regular eyedrop.;Primary end point(s): Within-subject pupildilation (compared to baseline) of a regular eyedrop and a microdrop at t=40 min.;Timepoint(s) of evaluation of this end point: 40 minutes after eyedrop administration

Secondary

MeasureTime frame
Secondary end point(s): Physical discomfort, experienced after administration of a microdrop and a regular eyedrop. Qualitative evaluation of the mydriatic reponse/time curves of both the microdrop and the regular eyedrop.;Timepoint(s) of evaluation of this end point: following both studysessions

Countries

Netherlands

Contacts

Public ContactSecretariaat Ziekenhuisapotheek

St. Elisabeth Ziekenhuis

0031135625

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026